Trinity Medical Center Adds Masimo Patient SafetyNet™ as a High Vigilance Safeguard for Post-Surgical Patients Leading Alabama Hospital Leverages Masimo SET® Pulse Oximetry for Oxygenation Monitoring and Masimo rainbow® Acoustic Monitoring for Ventilation Monitoring
BIRMINGHAM, Ala. and IRVINE, Calif., Nov. 12, 2012 /PRNewswire/ -- Masimo (NASDAQ: MASI) and Trinity Medical Center announced today the successful installation of Masimo Patient SafetyNet™, clinically shown to reduce rapid response activations and intensive care unit (ICU) transfers, while offering significant potential cost savings.1
Trinity joins a growing list of outstanding hospitals using Patient SafetyNet to track the underlying physiological conditions of post-surgical patients and detect changes or abnormalities that signal declining health status in real-time. When a patient's condition deteriorates, the system automatically sends wireless alerts directly to clinicians – prompting a potentially lifesaving response to the patient's bedside.
Trinity also is using rainbow® Acoustic Monitoring, which noninvasively and continuously measures a patient's respiration rate using an innovative adhesive sensor with an integrated acoustic transducer that is easily and comfortably applied to the patient's neck. Acoustic Respiration Rate (RRa™) is a breakthrough measurement that facilitates earlier detection of respiratory compromise and patient distress – especially important for post-surgical patients receiving patient-controlled analgesia for pain management, as the sedation can induce respiratory depression and place patients at considerable risk of serious injury or death.2-4
"Incorporating new technologies plays a key role in nurturing our culture of patient safety," said Keith Granger, President and CEO of Trinity Medical Center. "Our clinicians are finding this equipment to be a valuable tool as we work to continue to improve patient care."
Patient SafetyNet can help hospitals comply with The Joint Commission's Sentinel Event Alert released earlier this year that focused on the recommendation to continuously monitor post-surgical patients for possible adverse opioid effects.5 Fortunately, improved care does not need to come at a higher cost. Clinicians at Dartmouth-Hitchcock Medical Center in New Hampshire reported that using the Masimo Patient SafetyNet system on just one floor reduced ICU transfers and created an annual opportunity-cost savings of $1.48 million.1
Joe Kiani, Chairman and CEO of Masimo, stated: "We are happy that our breakthrough technologies help Trinity Medical Center's dedicated staff provide their patients with the best care possible. Each day we work to improve patient safety and reduce healthcare costs. With Masimo technologies on the general floor, clinicians can be confident their patients are being safely monitored even when they aren't at the bedside."
Trinity Medical Center has been named one of the nation's Top Performers on Key Quality Measures by The Joint Commission, the leading accreditor of health care organizations in the United States. The hospital was recognized by The Joint Commission for exemplary performance in using evidence-based clinical processes that are shown to improve care for certain conditions, including heart attack, heart failure, pneumonia, surgical care, children's asthma, stroke and venous thrombo embolism.
1 Taenzer A, Blike G, McGrath S, Pyke J, Herrick M, Renaud C, Morgan J. "Postoperative Monitoring – The Dartmouth Experience." Anesthesia Patient Safety Foundation Newsletter Spring-Summer 2012. Available online
2 Joint Commission on Accreditation of Healthcare Organizations. Sentinel event alert: patient controlled analgesia by proxy; JCAHO. 2004.
3 Institute for Safe Medication Practices. Safety issues with patient-controlled analgesia: Part I – How errors occur; ISMP. 2003.
4 Bird M. Acute pain management: a new area of liability for anesthesiologists; ASA Newsletter. 2007; 71:8.
5 The Joint Commission. Sentinel event alert: Safe use of opioids in hospitals; 2012
Trinity Medical Center is a tertiary care hospital serving residents of Birmingham, Alabama, and surrounding communities. The hospital offers programs and services in all medical and surgical areas. This includes oncology, cardiology, robotic surgery, orthopedics, neurology, women's health, mental health, digestive diseases, geriatrics, physical medicine and rehab, sports medicine, cardiac and pulmonary rehab, and emergency care. Trinity Medical Center has been named one of the nation's Top Performers on Key Quality Measures by The Joint Commission, the leading accreditor of health care organizations in the United States. The hospital was recognized by The Joint Commission for exemplary performance in using evidence-based clinical processes that are shown to improve care for certain conditions, including heart attack, heart failure, pneumonia and surgical care. For more information about Trinity Medical Center visit www.trinitymedicalonline.com.
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOCTM), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic MonitoringTM, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo's rainbow® SET® technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices. In 2012, Masimo acquired assets of Spire Semiconductor, LLC, maker of advanced light emitting diode (LED) and other advanced component-level technologies; and acquired PHASEIN AB, a developer and manufacturer of ultra-compact mainstream and sidestream capnography, multigas analyzers, and handheld capnometry solutions. Masimo SET® and Masimo rainbow® SET® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care … by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including: acoustic respiration rate (RRa™) and Patient SafetyNet contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN are under license from University HealthSystem Consortium.